We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A business joint venture (BV) comprising Teva Pharmaceutical and Takeda Pharmaceutical in Japan is set to divest the majority of its generic and operational assets to Nichi-Iko Pharmaceutical.
Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.